RayzeBio, Inc. clinical trial pipeline

5 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 2 with minor changes only.

1. Notable

   TRACY-1 · 225Ac-DOTATATE (RYZ101) · ER+, HER2-negative…TRACY-1 · 225Ac-DOTATATE (RYZ101) · ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs

   Enrollment reopened

   Also in this update: Enrollment increased: 16 → 64 participants

   RayzeBio, Inc.·Phase 1/2· NCT06590857· Registry history of NCT06590857 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

2. Notable

   Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer…Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

   Recruitment opened

   Also in this update: Trial sites expanded: 1 → 4 locations

   RayzeBio, Inc.·Early Phase 1· NCT07671092· Registry history of NCT07671092 on ClinicalTrials.gov (opens the registry)

   Updated Sep 29, 2026

3. Notable

   Imaging Study in Metastatic Clear Cell RCC

   Recruitment opened

   Also in this update: Trial sites expanded: 1 → 4 locations

   RayzeBio, Inc.·Early Phase 1· NCT07671417· Registry history of NCT07671417 on ClinicalTrials.gov (opens the registry)

   Updated Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.